Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Liebl

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Clinical Therapeutics|March 8, 2006
Efficacy of biphasic insulin aspart in patients with type 2 diabetesSerge Halimi, Philip Raskin, Andreas Liebl, et al.
Journal of Diabetes Science and Technology|October 16, 2013
A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trialAndreas Liebl, Jaime Davidson, Henriette Mersebach, et al.
Journal of Diabetes Science and Technology|April 10, 2013
Continuous glucose monitoring: evidence and consensus statement for clinical useAndreas Liebl, Helmut R Henrichs, Lutz Heinemann, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 2, 2018
EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETESIldiko Lingvay, Yehuda Handelsman, Sultan Linjawi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 31, 2002
Bootstrap confidence intervals for costs-of-illness of type 2 diabetes mellitus in GermanyStefan Wagenpfeil, Albrecht Neiss, Anita Goertz, et al.
Journal of Diabetes Science and Technology|March 12, 2015
HypoDE: Research Design and Methods of a Randomized Controlled Study Evaluating the Impact of Real-Time CGM Usage on the Frequency of CGM Glucose Values <55 mg/dl in Patients With Type 1 Diabetes and Problematic Hypoglycemia Treated With Multiple Daily InjectionsLutz Heinemann, Dorothee Deiss, Norbert Hermanns, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 13, 2013
Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: a1chieve sub-analysisHoosen Randeree, Andreas Liebl, Issam Hajjaji, et al.
Diabetes, Obesity & Metabolism|July 2, 2026
Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8)Krzysztof Strojek, Andreas Liebl, Neha Narendra Mumbaikar, et al.
Diabetes, Obesity & Metabolism|December 16, 2018
A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetesJoseph Tibaldi, Martin Hadley-Brown, Andreas Liebl, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 29, 2012
Clinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATEAndreas Liebl, Steven Jones, Alberto Goday, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Clinical Therapeutics|March 8, 2006
Efficacy of biphasic insulin aspart in patients with type 2 diabetesSerge Halimi, Philip Raskin, Andreas Liebl, et al.
Journal of Diabetes Science and Technology|October 16, 2013
A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trialAndreas Liebl, Jaime Davidson, Henriette Mersebach, et al.
Journal of Diabetes Science and Technology|April 10, 2013
Continuous glucose monitoring: evidence and consensus statement for clinical useAndreas Liebl, Helmut R Henrichs, Lutz Heinemann, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 2, 2018
EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETESIldiko Lingvay, Yehuda Handelsman, Sultan Linjawi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 31, 2002
Bootstrap confidence intervals for costs-of-illness of type 2 diabetes mellitus in GermanyStefan Wagenpfeil, Albrecht Neiss, Anita Goertz, et al.
Journal of Diabetes Science and Technology|March 12, 2015
HypoDE: Research Design and Methods of a Randomized Controlled Study Evaluating the Impact of Real-Time CGM Usage on the Frequency of CGM Glucose Values <55 mg/dl in Patients With Type 1 Diabetes and Problematic Hypoglycemia Treated With Multiple Daily InjectionsLutz Heinemann, Dorothee Deiss, Norbert Hermanns, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 13, 2013
Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: a1chieve sub-analysisHoosen Randeree, Andreas Liebl, Issam Hajjaji, et al.
Diabetes, Obesity & Metabolism|July 2, 2026
Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8)Krzysztof Strojek, Andreas Liebl, Neha Narendra Mumbaikar, et al.
Diabetes, Obesity & Metabolism|December 16, 2018
A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetesJoseph Tibaldi, Martin Hadley-Brown, Andreas Liebl, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 29, 2012
Clinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATEAndreas Liebl, Steven Jones, Alberto Goday, et al.
Pageof 5